Malignant Reproductive System Neoplasm

In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC)

PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC

In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC)

PMID 28242752 · de Bono et al., 2017 · Open in CIViC

Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC)

PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC)

PMID 26740259 · Harter et al., 2016 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC)

PMID 27908594 · Swisher et al., 2017 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proli… (full text at CIViC)

PMID 21278246 · Konecny et al., 2011 · Open in CIViC

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis.

PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC

Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the surviva… (full text at CIViC)

PMID 26204491 · Yang et al., 2015 · Open in CIViC

The effect of high CCNE1 expression on PD0332991 (palbociclib) sensitivity was observed in cell lines. One PD0332991 sensitive cell line, HEY, was engineered to constitutively express CCNE1 (HEY-CCNE… (full text at CIViC)

PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC

High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).

PMID 26625204 · Darb-Esfahani et al., 2016 · Open in CIViC

In a clinical study including 59 stage III-IV ovarian cancer patients with peritoneal disseminated tumors, Kaplan-Meier analysis showed a significant association between CD44v6 high expression and wor… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC)

PMID 11136572 · Costa et al., 2001 · Open in CIViC

In an in vitro study using docetaxel-resistant PC-3R cells, knockdown with CD44v8-10 siRNAs increased sensitivity to docetaxel (p < 0.05) compared to negative control.

PMID 32642575 · Kato et al., 2020 · Open in CIViC

A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC)

PMID 29169524 · Cheema et al., 2017 · Open in CIViC

In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and redu… (full text at CIViC)

PMID 24240700 · Bajrami et al., 2014 · Open in CIViC

In prostate cancer models, CDK12 loss impaired homologous recombination deficiency and sensitized cells to PARP inhibitors (olaparib, rucaparib, talazoparib, veliparib) in a gene dosage-dependent mann… (full text at CIViC)

PMID 39321214 · Chou et al., 2024 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC